Strides Pharma Science Ltd (IN:STAR)
:STAR
Want to see IN:STAR full AI Analyst Report?
STAR Stock Chart & Stats
₹950.75
-₹13.60(-1.99%)
At close: 4:00 PM EST
₹950.75
-₹13.60(-1.99%)
Day’s Range― - ―
52-Week Range₹769.60 - ₹1,231.45
Previous CloseN/A
Volume639.08K
Average Volume (3M)12.54K
Market Cap
₹90.14B
Enterprise Value₹117.93B
Total Cash (Recent Filing)₹2.27B
Total Debt (Recent Filing)₹18.44B
Price to Earnings (P/E)16.2
Beta0.86
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.41%
Share Statistics
EPS (TTM)43.13
Shares Outstanding92,172,714
10 Day Avg. Volume13,417
30 Day Avg. Volume12,536
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)2.78
Price to Sales (P/S)1.78
P/FCF Ratio71.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)71.07
Revenue Forecast (FY)₹57.61B
Bulls Say, Bears Say
Bulls Say
Diversified Commercial FootprintA presence in both regulated and semi-regulated markets and multiple revenue streams (own sales, partner distribution, contract manufacturing) reduces single-market dependency. This durable commercial diversification supports steadier revenue and mitigates localized regulatory or pricing shocks over months.
Profitability Turnaround And MarginsReturn to profitable operations with materially improved gross and net margins indicates stronger earnings power from pricing, product mix, or cost control. Sustained margins enhance internal funding for R&D, quality upgrades and commercialization over the medium term, improving resilience.
Improving Leverage And ROE RecoveryMaterial reduction in leverage and a rebound in ROE reflect improved balance-sheet discipline and capital efficiency. Lower relative leverage provides structural flexibility for capex, regulatory compliance or selective M&A, reducing solvency risk across the coming months.
Bears Say
Weak Free Cash Flow ConversionDespite accounting profits, weak and volatile free cash flow limits internal funding capacity and raises questions about earnings quality. Low conversion constrains ability to reinvest, reduce debt or sustain dividends without external financing, a structural constraint over the medium term.
Historic Earnings VolatilityThe company’s recent profits follow multiyear losses and margin swings, showing execution and cycle risk. Such historical volatility implies that returns depend on maintaining approvals, pricing and operational execution, creating persistent uncertainty about sustainability.
Meaningful Absolute Debt LevelWhile leverage ratios improved, material absolute debt can pressure cash flow during downturns or require refinancing. Coupled with inconsistent FCF, this limits strategic flexibility and raises refinancing and interest-rate sensitivity risks over the next several months.
Strides Pharma Science Ltd News
STAR FAQ
What was Strides Pharma Science Ltd’s price range in the past 12 months?
Strides Pharma Science Ltd lowest stock price was ₹769.60 and its highest was ₹1231.45 in the past 12 months.
What is Strides Pharma Science Ltd’s market cap?
Strides Pharma Science Ltd’s market cap is ₹90.14B.
When is Strides Pharma Science Ltd’s upcoming earnings report date?
Strides Pharma Science Ltd’s upcoming earnings report date is Aug 05, 2026 which is in 55 days.
How were Strides Pharma Science Ltd’s earnings last quarter?
Strides Pharma Science Ltd released its earnings results on May 18, 2026. The company reported ₹13.77 earnings per share for the quarter, beating the consensus estimate of N/A by ₹13.77.
Is Strides Pharma Science Ltd overvalued?
According to Wall Street analysts Strides Pharma Science Ltd’s price is currently Overvalued.
Does Strides Pharma Science Ltd pay dividends?
Strides Pharma Science Ltd pays a Annually dividend of ₹4 which represents an annual dividend yield of 0.41%. See more information on Strides Pharma Science Ltd dividends here
What is Strides Pharma Science Ltd’s EPS estimate?
Strides Pharma Science Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Strides Pharma Science Ltd have?
Strides Pharma Science Ltd has 92,172,714 shares outstanding.
What happened to Strides Pharma Science Ltd’s price movement after its last earnings report?
Strides Pharma Science Ltd reported an EPS of ₹13.77 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.316%.
Which hedge fund is a major shareholder of Strides Pharma Science Ltd?
Currently, no hedge funds are holding shares in IN:STAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Strides Pharma Science Ltd
Strides Pharma Science Limited is a pharmaceutical company that focuses on the development, production, and worldwide commercialization of medicinal products. Its extensive global footprint spans Africa, Australia, North America, Europe, Asia, India, and various other international markets. The company's operations are structured into two distinct segments: Pharmaceutical and Biopharmaceutical. It provides a diverse range of generic pharmaceuticals, available in multiple formats including tablets, hard and soft gelatin capsules, sachets, liquids, nasal sprays, powders, solids, ointments, and creams. Furthermore, Strides Pharma Science creates branded generic offerings for treating chronic ailments such as women's health issues, central nervous system disorders, cardiovascular conditions, diabetes, dermatological concerns, and probiotic support, marketed under brands like Renerve, Unibrol, Combiart, Duotab, and Vitafer. For institutional business, the company supplies drugs targeting infectious diseases, including anti-retrovirals, anti-malarials, anti-tuberculosis, and Hepatitis treatments. Incorporated in 1990, the company is headquartered in Bengaluru, India. It was formerly known as Strides Shasun Limited before adopting its current name in July 2018.
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Laurus Labs Ltd.
―
Piramal Pharma Limited
―
Sun Pharmaceutical Industries Limited
―